Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

The stock of the pharmaceutical company, Lupin is quoting higher for the sixth straight trading day; it has rallied 10 per ...

Lupin Ltd. acquires Huminsulin range from Eli Lilly, strengthening its position in the Indian diabetes market.

There is a significant Indian population affected with diabetes for both Type 1 and Type 2 Diabetes Mellitus, where Insulin ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

Huminsulin is used for adult and pediatric patient with Type 1 and Type 2 diabetes mellitus that aids in regulation of blood ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...